One of the most effective ways to reduce overtreatment of prostate cancer is to limit its detection in men with low-risk disease. Although many data are currently missing, we foresee a future with reduced prostate-specific antigen (PSA) testing in men selected through baseline PSA values or genetic predisposition. Then selective biopsy using multiparametric magnetic resonance imaging and longitudinal biomarkers will play a role.
The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer-The Problem Is How to Avoid Finding These Cancers
Gandaglia G;Briganti A;SALONIA, ANDREA;MONTORSI , FRANCESCO
2016-01-01
Abstract
One of the most effective ways to reduce overtreatment of prostate cancer is to limit its detection in men with low-risk disease. Although many data are currently missing, we foresee a future with reduced prostate-specific antigen (PSA) testing in men selected through baseline PSA values or genetic predisposition. Then selective biopsy using multiparametric magnetic resonance imaging and longitudinal biomarkers will play a role.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
